Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The group usually releases upbeat results with huge surprise rates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Based on current prices, the company has particularly high valuation levels.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, EPS estimates made by Thomson-Reuters analysts have been revised downwards.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GILEAD SCIENCES8.00%100 185
VERTEX PHARMACEUTICALS18.38%45 900
REGENERON PHARMACEUTICALS-2.35%38 962
GENMAB9.33%10 874
NEUROCRINE BIOSCIENCES, INC..33.30%9 332
BLUEBIRD BIO INC1.26%8 969
SAREPTA THERAPEUTICS INC139.59%8 881
BEIGENE LTD (ADR)73.18%8 823
TONGHUA DONGBAO PHARMACEUTI..10.57%7 744
EXELIXIS, INC.-29.97%6 335
LOXO ONCOLOGY INC107.78%5 329
AGIOS PHARMACEUTICALS INC59.28%5 252
BIOCON LTD5.97%4 992
HUALAN BIOLOGICAL ENGINEERI..--.--%4 789
PEPTIDREAM INC12.60%4 783
MADRIGAL PHARMACEUTICALS IN..212.72%4 459
More Results
Financials ($)
Sales 2018 20 806 M
EBIT 2018 10 735 M
Net income 2018 6 406 M
Debt 2018 12 164 M
Yield 2018 2,94%
P/E ratio 2018 15,69
P/E ratio 2019 14,31
EV / Sales 2018 5,40x
EV / Sales 2019 5,51x
Capitalization 100 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart GILEAD SCIENCES
Duration : Period : Day
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Duration : Period : Week
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders